Cytotoxic T-lymphocyte-associated protein 4 mRNA (CTLA4 mRNA) (CTLA4 mRNA)

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) mRNA is the transcript of the CTLA4 gene, which encodes a critical inhibitory receptor found on the surface of T cells (Source: UniProt P16410). The resulting CTLA-4 protein functions as an immune checkpoint by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells, effectively dampening T-cell activation and proliferation (Source: StatPearls, Immune Checkpoint Inhibitors). In many cancers, the CTLA-4 pathway is exploited to suppress anti-tumor immune responses, making the downregulation of this pathway a primary goal in immuno-oncology (Source: PubMed PMID: 28783702). Targeting the CTLA4 mRNA or pre-mRNA using RNA-based modalities like small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs) allows for the specific reduction of CTLA-4 protein levels at the source (Source: PubMed PMID: 20601469). This approach aims to enhance the activity of cytotoxic T lymphocytes against tumor cells while potentially offering different pharmacokinetic properties compared to traditional monoclonal antibodies (Source: Journal of Controlled Release, 2015). Additionally, modulating the alternative splicing of CTLA4 pre-mRNA can influence the production of soluble CTLA-4 (sCTLA-4), which has distinct roles in immune regulation and autoimmune disease pathogenesis (Source: PubMed PMID: 11544324).

Other names

CD152 mRNACTLA-4 transcriptCytotoxic T-lymphocyte-associated serine esterase 4 mRNA

Reduction of CTLA-4 protein expression via RNA interference (siRNA) or RNase H-mediated mRNA degradation (ASO), or modulation of alternative splicing of pre-mRNA to alter isoform ratios.